Benzinga | Aug 10, 2021 07:53AM EDT

UBS Downgrades Biohaven Pharma Hldgs to Neutral, Raises Price Target to $109

UBS analyst Esther Rajavelu downgrades Biohaven Pharma Hldgs (NYSE:BHVN) from Buy to Neutral and raises the price target from $108 to $109.